Bloomberg - Evening Briefing - The Covid pill dilemma
|
||||||||||||||
|
||||||||||||||
|
||||||||||||||
|
Older messages
Omicron is looking weaker
Thursday, December 23, 2021
Bloomberg's Evening Briefing View in browser Bloomberg The omicron variant of Covid-19 may be less likely to land patients in the hospital than the delta strain, according to three studies of
Covid pills are coming
Tuesday, December 21, 2021
Bloomberg's Evening Briefing View in browser Bloomberg The US Food and Drug Administration is poised to authorize a pair of pills from Pfizer and Merck to treat Covid-19, a potential milestone in
The Manchin downgrade
Tuesday, December 21, 2021
Bloomberg's Evening Briefing View in browser Bloomberg A third dose of Moderna's Covid-19 vaccine significantly increased antibody levels against the omicron variant, the company said, adding
America’s omicron disconnect
Saturday, December 18, 2021
Bloomberg's Weekend Reading View in browser Bloomberg Follow Us Get the newsletter Just when it seemed Americans could start half-thinking about a return to normalcy, the omicron variant presented
Omicron spikes
Friday, December 17, 2021
Bloomberg's Evening Briefing View in browser Bloomberg Around every corner there seems to be new research on this latest, still-mysterious variant of the coronavirus. Scientists are banging away
You Might Also Like
Metal is back
Wednesday, April 24, 2024
Bloomberg Evening Briefing View in browser Bloomberg Metal is back. Some of the world's biggest energy trading companies are returning to the sector years after getting burnt in notoriously
👀 Meta spilled the beans
Wednesday, April 24, 2024
Meta revealed its first-quarter results | Gucci-owner Kering's results weren't front-cover material | Finimize TOGETHER WITH Hi Reader, here's what you need to know for April 25th in 3:16
Lots of things emerge as spring begins — and we’re not talking about flowers
Wednesday, April 24, 2024
Prepare for the ugly side of warmer months. ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Issue #235: Is chasing high APYs worth it?
Wednesday, April 24, 2024
plus Roger goes viral + themed cruises ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Harry's Take 4-24-24 Have You Saved Enough?
Wednesday, April 24, 2024
Life Expectancy and Retirement ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Adapt or Atrophy? - Issue #465
Wednesday, April 24, 2024
This week, we examine the resilience and transformation driving the fintech and logistics sectors. April 24, 2024 FinTech Weekly plunges into the heart of a sector that refuses to stand still. This
The 10-Minute Trader [One Easy Option Trade]
Wednesday, April 24, 2024
The following is a third-party sponsored message. It should not be considered a recommendation or endorsement by HS Dent Publishing. Hugh Grossman Fellow Investor, Hugh Grossman here, This simple, set-
Quantifying the macroeconomic impact of geopolitical risk
Wednesday, April 24, 2024
Julian Reynolds Policymakers and market participants consistently cite geopolitical developments as a key risk to the global economy and financial system. But how can one quantify the potential
Banning the non-compete
Tuesday, April 23, 2024
Bloomberg Evening Briefing View in browser Bloomberg In a major victory for prospective employees looking down the barrel of a non-compete clause, the US Federal Trade Commission voted Tuesday to adopt
📉 Tesla's revenue couldn't steer itself
Tuesday, April 23, 2024
Finimize TOGETHER WITH Hi Reader, here's what you need to know for April 24th in 3:09 minutes. 🚎 If this newsletter makes your morning subway commute a little less hideous, take a look at our